Coherus BioSciences Stock Price and Value Analysis

Should you buy Coherus BioSciences stock? (NasdaqGM:CHRS). Let's see how it does in our automated value investing analysis system.

CHRS Free Cash Flow Trend

Free Cash Flow trendline for CHRS
Free Cash Flow trendline for Coherus BioSciences

Hmm, we can't give any reliable projection for Coherus BioSciences's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company has fluctuating growth.
  • This company is solid.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the CHRS Numbers

CHRS Price
(Coherus BioSciences stock price per share)
[?] PE Ratio versus Sector 55% lower than other Healthcare stocks
[?] PE Ratio versus Industry 84% lower than other Biotechnology stocks
[?] Cash Yield -8.59%
[?] Free Cash Flow Jitter 32%

Is Coherus BioSciences Stock on Sale?

Based on our analysis, we believe that you should not buy Coherus BioSciences right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy CHRS Stock?

Does Coherus BioSciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.